Free Trial

Reneo Pharmaceuticals (RPHM) Stock Forecast & Price Target

$1.73
-0.10 (-5.46%)
(As of 05/23/2024 ET)

Reneo Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce
Based on 8 Analyst Ratings

Consensus Price Target

$11.01
536.56% Upside
High Forecast$35.55
Average Forecast$11.01
Low Forecast$1.50
TypeCurrent Forecast
5/24/23 to 5/23/24
1 Month Ago
4/24/23 to 4/23/24
3 Months Ago
2/23/23 to 2/23/24
1 Year Ago
5/24/22 to 5/24/23
Consensus Rating
Reduce
Reduce
Reduce
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
2 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
7 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$11.01$18.14$18.14$28.00
Forecasted Upside536.56% Upside533.07% Upside533.07% Upside654.72% Upside
Get Reneo Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RPHM and its competitors with MarketBeat's FREE daily newsletter.

RPHM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RPHM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Reneo Pharmaceuticals Stock vs. The Competition

TypeReneo PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
1.88
2.70
2.49
Consensus RatingReduceModerate BuyHold
Predicted Upside536.56% Upside838.74% Upside10.43% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/14/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kapoor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.50-5.66%
12/15/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Market Perform
12/15/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
12/14/2023LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
12/14/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Underperform
12/14/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Minter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
12/14/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$25.00 ➝ $4.00+247.82%
12/14/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$28.00 ➝ $3.00+160.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:44 PM ET.

RPHM Frequently Asked Questions

What is Reneo Pharmaceuticals's stock forecast and purchase recommendation?

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Reneo Pharmaceuticals is $11.01, with a high forecast of $35.55 and a low forecast of $1.50. The consensus rating for Reneo Pharmaceuticals stock is Reduce based on the current 1 sell rating and 7 hold ratings for RPHM. Learn more on RPHM's analyst rating history.

Do Wall Street analysts like Reneo Pharmaceuticals more than its competitors?

Analysts like Reneo Pharmaceuticals less than other "medical" companies. The consensus rating for Reneo Pharmaceuticals is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RPHM compares to other companies.

Does Reneo Pharmaceuticals's stock price have much upside?

According to analysts, Reneo Pharmaceuticals's stock has a predicted upside of 445.95% based on their 12-month stock forecasts.

What analysts cover Reneo Pharmaceuticals?

Reneo Pharmaceuticals has been rated by research analysts at HC Wainwright in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:RPHM) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners